Showing 1 - 3 results of 3 for search 'Vivekananda Budamagunta', query time: 0.03s Refine Results
  1. 1
    DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

    DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas by Yonghan He, Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan, Dinesh Thummuri, Yuma T. Ortiz, Xin Zhang, Dongwen Lv, Janet S. Wiegand, Wen Li, Adam C. Palmer, Guangrong Zheng, David M. Weinstock, Daohong Zhou

    Published 2020-07-01
    Get full text
    Article
  2. 2
    Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

    Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice by Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J. Kaye, Daohong Zhou

    Published 2023-01-01
    Get full text
    Article
  3. 3
    Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

    Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity by Yonghan He, Xuan Zhang, Jianhui Chang, Ha-Neui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dongwen Lv, Lin Song, Wen Li, Dinesh Thummuri, Yaxia Yuan, Janet S. Wiegand, Yuma T. Ortiz, Vivekananda Budamagunta, Jennifer H. Elisseeff, Judith Campisi, Maria Almeida, Guangrong Zheng, Daohong Zhou

    Published 2020-04-01
    Get full text
    Article

Search Tools: